• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction

byGursharan SohiandYuchen Dai
March 16, 2023
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were found to increase quality-adjusted life-years at a cost of $26,000 compared to standard of care alone.

2. Amongst 1000 probabilistic models, 59.1% predicted SGLT2-I added intermediate value, and 40.9% predicted low value.

Level of Evidence Rating: 2 (Good)

Study Rundown: Sodium-glucose cotransporter-2 inhibitor (SGLT2-I) medications have become central to managing heart failure, diabetes mellitus and renal disease in recent years. Although associated with significant clinical benefits, SGLT2-I remains a proprietary medication with an annual cost of approximately $8,000 USD. The present study by Cohen et al. sought to determine the cost-effectiveness of SGLT2-I added to the standard of care management of heart failure with preserved ejection fraction.

Over 2.3 years, adding SGLT2-I to the standard of care reduced mean hospitalizations due to heart failure and increased mean survival from 7.73 to 7.95 years. Lifetime quality-adjusted life-years (QALYs) also increased from 5.27 to 5.46, with a cost increase of $26 312. The lifetime ICER of adding SGLT2-I to the standard of care was $141 200 per QALY gained. Across 1000 probabilistic iterations, this was found to be an intermediate or low-value intervention. Interestingly, if half of all eligible patients in the United States were to receive SGLT2-I therapy in addition to the standard of care, the budget for healthcare expenditures would have to increase by approximately $4.3 billion annually.

This economic analysis by Cohen et al. demonstrated that SGLT2-I medications are of intermediate cost effectiveness, increasing quality-adjusted life years by 0.19 years and associated with a cost increase of $26,300. The cost-effectiveness of this strategy would be improved by lowering medication costs and wholesale acquisition costs. A strength of this study is that clinical data were derived from two large, randomized controlled trials representing tier-one evidence. Additionally, the thoroughness of the analysis demonstrated a high degree of real-world applicability. A major limitation of this study is the inability to account for all health benefits associated with SGLT2-I, including renoprotective effects. Further studies should focus on identifying strategies to reduce costs associated with this drug class and to identify the subgroup of patients for which therapy is cost-effective.

Click here to read this study in JAMA Cardiology

RELATED REPORTS

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

Optimal implementation of sodium-glucose cotransporter-2 inhibitors in US patients with heart failure estimated to cause a significant reduction in worsening heart failure events over 3 years

Click to read an accompanying editorial in JAMA Cardiology

Relevant reading: Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: the EMPEROR-preserved trial

In-Depth [cost-effectiveness analysis]: A lifetime cost-effectiveness analysis from the perspective of the United States healthcare sector was conducted. A Markov model was used to predict the lifetime costs associated with adding an SGLT2-I (empagliflozin or dapagliflozin) to the standard of care for heart failure with preserved ejection fraction. Patient eligibility criteria for inclusion in the Markov model are derived from the EMPEROR-preserved and DELIVER trials. The trial duration was 2.3 years; therefore, mortality rates for this period were derived from the results of these studies; hospitalizations and risk of death from heart failure were derived from the control arm data in each.

In the EMPEROR-preserved and DELIVER trials, SGLT2-I significantly decreased hospitalizations due to heart failure (hazard ratio 0.74, 95% confidence interval 0.67-0.83) and a trend towards reduced cardiovascular death (0.88, 0.77-1.00). The base-case cost of annual SGLT2-I therapy was $4506, with sensitivity analysis scenarios ranging from $1415-6620. Finally, quality of life data was derived from the Kansas City Cardiomyopathy Questionnaire.

Over 2.3 years, adding SGLT2-I to the standard of care was found to reduce mean hospitalizations due to heart failure (from 0.74 [0.65-0.87] to 0.53 [0.44-0.63]) and increase mean survival from 7.73 (7.65-7.80) to 7.95 (7.68-8.20) years. Lifetime quality-adjusted life-years (QALYs) were also increased from 5.27 (5.22-5.33) to 5.46 (5.29-5.62), accompanied by a cost increase of $26 312 ($20 290-$31 722). The lifetime ICER of adding SGLT2-I to the standard of care was $141 200 per QALY gained. Across 1000 probabilistic iterations, this was found to be an intermediate (59.1%) or low (40.9%) value intervention.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cost effectiveness analysisDELIVEREMPEROR-PreservedHFpEF (heart failure with preserved ejection fractionSGLT-2 inhibitors
Previous Post

Ultrasound ablation of globus pallidus reduces Parkinson’s disease motor symptoms

Next Post

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

February 5, 2023
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

November 30, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Optimal implementation of sodium-glucose cotransporter-2 inhibitors in US patients with heart failure estimated to cause a significant reduction in worsening heart failure events over 3 years

November 12, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER

October 16, 2022
Next Post
Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT

Black patients with pulmonary fibrosis may have worse outcomes compared to other populations

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Prior COVID-19 infection may result in poorer sleep health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
  • Spirituality, among many other factors, may help promote healthy ageing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options